Hematopoietic Stem Cell Therapy for Wiskott–Aldrich Syndrome: Improved Outcome and Quality of Life
Authors:
Open Access
- 1 June 2021
- journal article
- review article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 12, 435-447
Abstract
The Wiskott–Aldrich syndrome (WAS) is an X-linked disorder caused by mutations in the WAS gene resulting in congenital thrombocytopenia, eczema, recurrent infections and an increased incidence of autoimmune diseases and malignancies. Without curative therapies, affected patients have diminished life expectancy and reduced quality of life. Since WAS protein (WASP) is constitutively expressed only in hematopoietic stem cell-derived lineages, hematopoietic stem cell transplantation (HSCT) and gene therapy (GT) are well suited to correct the hematologic and immunologic defects. Advances in high-resolution HLA typing, new techniques to prevent GvHD allowing the use of haploidentical donors, and the introduction of reduced intensity conditioning regimens with myeloablative features have increased overall survival (OS) to over 90%. The development of GT for WAS has provided basic knowledge into vector selection and random integration of various viral vectors into the genome, with the possibility of inducing leukemogenesis. After trials and errors, inactivating lentiviral vectors carrying the WAS gene were successfully evaluated in clinical trials, demonstrating cure of the disease except for insufficient resolution of the platelet defect. Thus, 50 years of clinical evaluation, genetic exploration and extensive clinical trials, a lethal syndrome has turned into a curable disorder.Keywords
This publication has 85 references indexed in Scilit:
- Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative studyBlood, 2011
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: Advances in Biology and Future Directions for TreatmentImmunology and Allergy Clinics of North America, 2010
- Antiplatelet antibodies in WASP(−) mice correlate with evidence of increased in vivo platelet consumptionExperimental Hematology, 2009
- G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasiaHaematologica, 2009
- A large kindred with X‐linked neutropenia with an I294T mutation of the Wiskott‐Aldrich syndrome geneBritish Journal of Haematology, 2008
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Journal of Clinical Investigation, 2008
- Development of lentiviral gene therapy for Wiskott Aldrich syndromeExpert Opinion on Biological Therapy, 2008
- WASP regulates suppressor activity of human and murine CD4+CD25+FOXP3+ natural regulatory T cellsJournal of Experimental Medicine, 2007
- Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasisJournal of Clinical Investigation, 2007